Kymera raises $65M series B

Protein degradation company Kymera Therapeutics LLC (Cambridge, Mass.) closed an untranched $65 million series B round to bring its lead program into the clinic.

Kymera is developing heterobifunctional molecules that bind to both an E3 ubiquitin ligase and a target protein, driving ubiquitination and degradation of targets for cancer, autoimmune diseases and inflammation. ...